ArriVent BioPharma, Inc. Common Stock Market Cap ($641.99 Million)
Market Cap & Net Worth: ArriVent BioPharma, Inc. Common Stock (AVBP)
ArriVent BioPharma, Inc. Common Stock market cap. ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP) has a market capitalization of $641.99 Million ($641.99 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10630 globally and #2842 in its home market, demonstrating a -15.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ArriVent BioPharma, Inc. Common Stock's stock price $13.02 by its total outstanding shares 49307729 (49.31 Million). Also see ArriVent BioPharma, Inc. Common Stock (AVBP) cash flow conversion for how efficiently the company converts equity into cash flow.
ArriVent BioPharma, Inc. Common Stock Market Cap History (2024–2026)
ArriVent BioPharma, Inc. Common Stock market cap history from 2024 to 2026. Data shows change from $1.33 Billion to $641.99 Million (-11.01% CAGR). Check ArriVent BioPharma, Inc. Common Stock stock quote for real-time trading data and today's change.
Index Memberships
ArriVent BioPharma, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.02% | #296 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1108 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.04% | #175 of 263 |
Weight: ArriVent BioPharma, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ArriVent BioPharma, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ArriVent BioPharma, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ArriVent BioPharma, Inc. Common Stock equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AVBP by Market Capitalization
Companies near ArriVent BioPharma, Inc. Common Stock in the global market cap rankings as of November 5, 2026. Also see ArriVent BioPharma, Inc. Common Stock (AVBP) total assets for a full breakdown of the balance sheet.
Key companies related to ArriVent BioPharma, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of ArriVent BioPharma, Inc. Common Stock (2024–2026)
Market capitalization of ArriVent BioPharma, Inc. Common Stock from 2024 to today. Between 2024 and today, ArriVent BioPharma, Inc. Common Stock's market cap moved from $1.33 Billion to $ 641.99 Million, with a yearly change of -11.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $641.99 Million | -35.29% |
| 2025 | $992.07 Million | -25.48% |
| 2024 | $1.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of ArriVent BioPharma, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $641.99 Million USD |
| MoneyControl | $641.99 Million USD |
| MarketWatch | $641.99 Million USD |
| marketcap.company | $641.99 Million USD |
| Reuters | $641.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more